<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03397264</url>
  </required_header>
  <id_info>
    <org_study_id>OPT-302-1003</org_study_id>
    <nct_id>NCT03397264</nct_id>
  </id_info>
  <brief_title>A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema</brief_title>
  <official_title>Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Opthea Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Opthea Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two part, multi-center study consisting of a Phase 1b open label, sequential dose
      escalation followed by a Phase 2a randomized, double-masked, dose expansion evaluating
      OPT-302 in combination with aflibercept in participants with persistent central-involved
      Diabetic Macular Edema.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1b - sequential dose followed by Phase 2a - parallel arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Ph 1b open label; Ph 2a quadruple masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Safety and Tolerability will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events and CTC v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a: Proportion of participants achieving at least a 5 letter gain in BCVA compared to Baseline</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>BCVA will be measured according to Early Treatment Diabetic Retinopathy Score criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCVA</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Mean change in Best Corrected Visual Acuity (BCVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CST</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Mean change in central subfield thickness (CST) on spectral domain coherence tomography (SD-OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular Volume</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Mean change in macular volume on spectral domain coherence tomography (SD-OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Foveal Thickness</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Percent of eyes with CST with 50% or more reduction in excess foveal thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Early Treatment Diabetic Retinopathy Study (ETDRS) Score</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Percent of participants with a 2 step or more improvement in ETDRS Diabetic Retinopathy Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aflibercept (anti-Vascular Endothelial Growth Factor-A) Retreatment (Mean Time)</measure>
    <time_frame>Week 12 to Week 24</time_frame>
    <description>The mean time to re-treatment injections of aflibercept anti-VEGF-A therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aflibercept (anti-Vascular Endothelial Growth Factor-A) Retreatment (Number)</measure>
    <time_frame>Week 12 to Week 24</time_frame>
    <description>The number of re-treatment injections of aflibercept anti-VEGF-A therapy</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ph 1b: 2.0 mg aflibercept with 0.3 mg OPT-302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 0.3 mg OPT-302 intravitreal injection (0.05 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph 1b: 2.0 mg aflibercept with 1.0 mg OPT-302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 1.0 mg OPT-302 intravitreal injection (0.05 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph 1b: 2.0 mg aflibercept with 2.0 mg OPT-302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 2.0 mg OPT-302 intravitreal injection (0.05 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph 2a: 2.0 mg aflibercept with highest tested or MTD OPT-302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg aflibercept intravitreal injection (0.05 mL) followed highest tested or MTD from Phase 1b OPT-302 intravitreal injection (0.05 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph 2a: 2.0 mg aflibercept with sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>2.0 mg aflibercept intravitreal injection (0.05 mL) followed by sham intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Intravitreal injection</description>
    <arm_group_label>Ph 1b: 2.0 mg aflibercept with 0.3 mg OPT-302</arm_group_label>
    <arm_group_label>Ph 1b: 2.0 mg aflibercept with 1.0 mg OPT-302</arm_group_label>
    <arm_group_label>Ph 1b: 2.0 mg aflibercept with 2.0 mg OPT-302</arm_group_label>
    <arm_group_label>Ph 2a: 2.0 mg aflibercept with highest tested or MTD OPT-302</arm_group_label>
    <arm_group_label>Ph 2a: 2.0 mg aflibercept with sham</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OPT-302</intervention_name>
    <description>Intravitreal Injection</description>
    <arm_group_label>Ph 1b: 2.0 mg aflibercept with 0.3 mg OPT-302</arm_group_label>
    <arm_group_label>Ph 1b: 2.0 mg aflibercept with 1.0 mg OPT-302</arm_group_label>
    <arm_group_label>Ph 1b: 2.0 mg aflibercept with 2.0 mg OPT-302</arm_group_label>
    <arm_group_label>Ph 2a: 2.0 mg aflibercept with highest tested or MTD OPT-302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham intravitreal injection</intervention_name>
    <description>Sham (mock) intravitreal injection</description>
    <arm_group_label>Ph 2a: 2.0 mg aflibercept with sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of diabetic macular edema (DME) ≤ 2 year

          -  Persistent DME despite prior intravitreal anti-VEGF-A therapy with a sub-optimal
             response

          -  Three or more prior anti-VEGF-A therapy intravitreal injections

          -  EDTRS BCVA score ≤ 73 and ≥ 24 letters

        Exclusion Criteria:

          -  Ocular disorders or ocular treatments which may interfere with assessment of visual
             acuity, assessment of toxicity, or fundus photography in the Study Eye

          -  HbA1c ≥ 12% and/or recent signs of uncontrolled diabetes

          -  Any clinically significant disorder or condition or disease (e.g. cardiovascular,
             renal conditions) that would make the participant unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Willow Park</city>
        <state>Texas</state>
        <zip>76087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Parramatta</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Be'er Ya'aqov</city>
        <zip>703 5</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Reẖovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Tel Aviv Yafo</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Tiberias</city>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Jelgava</city>
        <zip>LV-3001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthea Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1050</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 1, 2018</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2018</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

